Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68071-2711

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-2711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2711 9)

This is a description of a medication called Duloxetine 20mg, specifically lot number 00000. It comes in a bottle of 90 capsules and the National Drug Code (NDC) is 68071-2711-09. Each capsule contains 22.4mg of Duloxetine Hydrochloride USP, equivalent to 20mg of Duloxetine. It is manufactured by unknown companies with NDC numbers 51991-746-90 and 68071-2711-9. The expiration date is 00-00 and the medication should be stored at a controlled temperature of 68-77°F. It also contains a warning to keep it out of reach of children.*

FDA Label Image

Chemical Structure (Duloxetine 01)

FDA Label Image

Figure 1 (Duloxetine 02)

The graph shows the proportion of patients with relapse over time from randomization to relapse (in days) for two different treatments: placebo and duloxetine delayed-release. The y-axis indicates the percentage of patients with relapse, while the x-axis indicates the time from randomization to relapse. The graph suggests that patients treated with duloxetine delayed-release tend to have a lower risk of relapse compared to those treated with placebo.*

FDA Label Image

Figure 2 (Duloxetine 03)

The graph shows the proportion of patients who experienced a relapse while taking either duloxetine delayed-release capsules or a placebo. The vertical axis represents the percentage of patients while the horizontal axis shows the time elapsed in days from randomization to relapse. The proportion of patients who experienced a relapse was lower in the duloxetine group compared to the placebo group.*

FDA Label Image

Figure 3 (Duloxetine 04)

FDA Label Image

Figure 4 (Duloxetine 05)

FDA Label Image

Figure 5 (Duloxetine 06)

The text describes a chart or table showing the percentage of improvement in pain experienced by patients. The chart likely includes three columns: "DUL 50 Twice Daily," "DUL 50mg Once Daily," and "Placebo," and each row of the chart shows the percentage of improvement for each medication.*

FDA Label Image

Figure 6 (Duloxetine 07)

Not available.*

FDA Label Image

Figure 8 (Duloxetine 08)

The text shows a chart displaying the percentage of patients improved in pain from a baseline, with a comparison between a placebo group and a group taking DUL 60/120 mg once daily. The chart measures improvement in increments of 10 from 0 to 100 on the x-axis.*

FDA Label Image

Figure 9 (Duloxetine 09)

This appears to be a graph showing the percentage of patients who saw improvement in pain from baseline, with the x-axis indicating different percentages and the y-axis indicating the dosage of a medication (placebo or DUL 60mg once daily). The graph also includes specific data points for each dosage.*

FDA Label Image

Figure 10 (Duloxetine 10)

This is a graph showing the percentage of patients improved with either a placebo or DULBO/120mg once daily, based on the percent improvement in pain from baseline. The graph also displays a percentage scale ranging from 0% to 100% and a horizontal axis featuring values ranging from 220 to 290.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.